Literature DB >> 10773878

Analysis of p73 in human borderline and invasive ovarian tumor.

S W Ng1, G K Yiu, Y Liu, L W Huang, M Palnati, S H Jun, R S Berkowitz, S C Mok.   

Abstract

p73 is a novel gene that has high sequence homology and similar gene structure to the tumor suppressor gene p53. We analysed p73 in seven ovarian carcinoma cell lines and a total of 63 human borderline and invasive ovarian tumor samples. Loss of heterozygosity at this locus was observed in 50% of invasive tumors but in none of the borderline tumors. Biallelic expression of the gene was observed in the heterozygous tumor tissues. Direct sequencing and single-strand conformation polymorphism analyses of the p73 cDNA sequence homologous to the highly mutatable region of p53 did not reveal any mutations. When compared to the primary cultures of normal human ovarian surface epithelial cells and immortalized cell lines, four of the seven ovarian carcinoma cell lines, 71% of the invasive tumors, and 92% of the borderline tumor tissues express elevated levels of p73 transcript. Except for the OVCA3 cell line, Western blot analysis of the nuclear extracts prepared from the cell lines showed concordant levels of p73 protein. Our analysis also demonstrated the expression of a spliced variant of p73 transcript with the omission of exon 2 solely in the cancer cell lines and invasive tumor tissues. This exon 2-spliced transcript would give rise to a truncated p73 protein without the N-terminal transactivation domain. In reminiscence of the dominant negative phenotype of the N-terminal truncated variants of another p53-related gene, p63, the expression of the truncated p73 variant form in ovarian tumors may play an important role in the pathogenesis of ovarian cancer.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10773878     DOI: 10.1038/sj.onc.1203512

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  11 in total

Review 1.  Evasion of anti-growth signaling: A key step in tumorigenesis and potential target for treatment and prophylaxis by natural compounds.

Authors:  A R M Ruhul Amin; Phillip A Karpowicz; Thomas E Carey; Jack Arbiser; Rita Nahta; Zhuo G Chen; Jin-Tang Dong; Omer Kucuk; Gazala N Khan; Gloria S Huang; Shijun Mi; Ho-Young Lee; Joerg Reichrath; Kanya Honoki; Alexandros G Georgakilas; Amedeo Amedei; Amr Amin; Bill Helferich; Chandra S Boosani; Maria Rosa Ciriolo; Sophie Chen; Sulma I Mohammed; Asfar S Azmi; W Nicol Keith; Dipita Bhakta; Dorota Halicka; Elena Niccolai; Hiromasa Fujii; Katia Aquilano; S Salman Ashraf; Somaira Nowsheen; Xujuan Yang; Alan Bilsland; Dong M Shin
Journal:  Semin Cancer Biol       Date:  2015-03-06       Impact factor: 15.707

2.  Preclinical activity of combined HDAC and KDM1A inhibition in glioblastoma.

Authors:  Melissa M Singh; Blake Johnson; Avinashnarayan Venkatarayan; Elsa R Flores; Jianping Zhang; Xiaoping Su; Michelle Barton; Frederick Lang; Joya Chandra
Journal:  Neuro Oncol       Date:  2015-03-19       Impact factor: 12.300

3.  p73 in Cancer.

Authors:  Alessandro Rufini; Massimiliano Agostini; Francesca Grespi; Richard Tomasini; Berna S Sayan; Maria Victoria Niklison-Chirou; Franco Conforti; Tania Velletri; Antonio Mastino; Tak W Mak; Gerry Melino; Richard A Knight
Journal:  Genes Cancer       Date:  2011-04

4.  Requirement for TP73 and genetic alterations originating from its intragenic super-enhancer in adult T-cell leukemia.

Authors:  Jolynn Zu Lin Ong; Rui Yokomori; Regina Wan Ju Wong; Tze King Tan; Ryuzo Ueda; Takashi Ishida; Shinsuke Iida; Takaomi Sanda
Journal:  Leukemia       Date:  2022-07-30       Impact factor: 12.883

5.  p53 Family: Role of Protein Isoforms in Human Cancer.

Authors:  Jinxiong Wei; Elena Zaika; Alexander Zaika
Journal:  J Nucleic Acids       Date:  2011-10-09

6.  N-(phosphonacetyl)-L-aspartate induces TAp73-dependent apoptosis by modulating multiple Bcl-2 proteins: potential for cancer therapy.

Authors:  A R M Ruhul Amin; V S Thakur; K Gupta; M K Agarwal; D N Wald; D M Shin; M L Agarwal
Journal:  Oncogene       Date:  2012-03-19       Impact factor: 9.867

7.  Detection of p73 antibodies in patients with various types of cancer: immunological characterization.

Authors:  O Tominaga; K Unsal; G Zalcman; T Soussi
Journal:  Br J Cancer       Date:  2001-01-05       Impact factor: 7.640

8.  p73 is over-expressed in vulval cancer principally as the Delta 2 isoform.

Authors:  J O'Nions; L A Brooks; A Sullivan; A Bell; B Dunne; M Rozycka; A Reddy; J A Tidy; D Evans; P J Farrell; A Evans; M Gasco; B Gusterson; T Crook
Journal:  Br J Cancer       Date:  2001-11-16       Impact factor: 7.640

9.  Prognostic value of increase in transcript levels of Tp73 DeltaEx2-3 isoforms in low-grade glioma patients.

Authors:  M Wager; J Guilhot; J-L Blanc; S Ferrand; S Milin; B Bataille; F Lapierre; S Denis; T Chantereau; C-J Larsen; L Karayan-Tapon
Journal:  Br J Cancer       Date:  2006-10-23       Impact factor: 7.640

10.  DeltaNp73, a dominant-negative inhibitor of wild-type p53 and TAp73, is up-regulated in human tumors.

Authors:  Alex I Zaika; Neda Slade; Susan H Erster; Christine Sansome; Troy W Joseph; Michael Pearl; Eva Chalas; Ute M Moll
Journal:  J Exp Med       Date:  2002-09-16       Impact factor: 14.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.